Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30987846 | 0.80 | CA12 (0.64) | CA12CA2CA9CA1KMT2A | |
| SCHEMBL9129433 | 0.78 | CA12 (0.61) | CA12CA2CA9CA1KMT2A | |
| SCHEMBL10155509 | 0.78 | CA12 (0.61) | CA12CA2CA9CA1KMT2A | |
| SCHEMBL5212044 | 0.77 | — | — | |
| SCHEMBL8406879 | 0.76 | CA12 (0.59) | CA12CA2CA9CA1KMT2A | |
| SCHEMBL5198300 | 0.76 | CA12 (0.59) | CA12CA2CA9CA1KMT2A | |
| Hydrochloric Acid SCHEMBL626137 | 0.74 | CA12 (0.57) | CA12CA2CA9CA1KMT2A | |
| SCHEMBL12064763 | 0.74 | CA12 (0.57) | CA12CA2CA9CA1KMT2A | |
| SCHEMBL10127435 | 0.73 | CA12 (0.55) | CA12CA2CA9CA1KMT2A | |
| SCHEMBL14255477 | 0.73 | CA12 (0.55) | CA12CA2CA9CA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | claimed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | claimed |
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | CA12 1900/4885CA2 236/4885CA9 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.